Marc Kamin, M.D. Joins PharmaNet Development Group as Vice President, Medical and Scientific Affairs, Neuroscience

PRINCETON, N.J., March 18 /PRNewswire/ -- PharmaNet Development Group, Inc., a leading provider of clinical development services to pharmaceutical, biotechnology, generic drug and medical device companies, announced today that Marc Kamin, M.D., has been appointed Vice President, Medical and Scientific Affairs, Neuroscience.  Dr. Kamin will serve in an advisory role to clients in the area of neuroscience and will provide medical support to PharmaNet project teams conducting neuroscience clinical studies.

Dr. Kamin is a neurologist, certified by the American Board of Psychiatry and Neurology, with twenty years experience in the pharmaceutical industry. Most recently, Dr. Kamin was at Johnson & Johnson, where he led the Central Trial Coordination group for Medical Affairs in Global Clinical Operations. Dr. Kamin has designed and managed trials in many areas of neuroscience including migraine, eating disorders, bipolar disorder, alcohol addiction, acute and chronic pain, multiple sclerosis, epilepsy, peripheral neuropathy, amyotrophic lateral sclerosis and fibromyalgia.

"We are delighted to have a physician of his caliber at the forefront of our neuroscience team," commented Dr. Pablo Fernandez, Senior Vice President, Worldwide Medical Affairs. "Marc's vast experience and valuable expertise strengthens our neuroscience service offering."

In addition to Dr. Kamin's appointment, PharmaNet Development Group has also enhanced its highly experienced neuroscience team with the previously announced appointment of Dr. Steven Leventer.

PharmaNet's already extensive neuroscience experience is based on the conduct of more than 160 neuroscience studies. With access to a large worldwide pool of neuroscience investigators, combined with in-house expertise and the appointments of industry-recognized experts, PharmaNet is well positioned for the conduct of neuroscience clinical development programs.

About PharmaNet Development Group, Inc.

PharmaNet Development Group, Inc., a global drug development services company, provides a comprehensive range of services to the pharmaceutical, biotechnology, generic drug and medical device industries. The Company offers early and late stage consulting, Phase I clinical studies and bioanalytical analyses, and Phase II, III and IV clinical development programs. With approximately 2,300 employees and more than 41 facilities throughout the world, PharmaNet is a recognized leader in outsourced clinical development. For more information, please visit our website at www.pharmanet.com.  

SOURCE PharmaNet Development Group, Inc.